GUTOCINS Oral oxytocin for abdominal pain
- Coordinator
- Universitat Wien, Austria
- Runs
- 1 June 2023 to 30 November 2024
- Status
- Finished
- EU funding
- €150k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101113137
What the project is doing
In the project's own words, from its summary on CORDIS.
Chronic abdominal pain is a widespread debilitating condition commonly associated with gastrointestinal disorders such as irritable bowel syndrome (IBS) and inflammatory bowel diseases (IBD). IBS and IBD affect more than 10% of the global population, leaving a severe and steadily growing socio-economic burden on society (€115 billion/year in Europe in direct and indirect health care costs). Adequate pain management for these conditions is imperative but remains challenging since classical analgesics are poorly effective, associated with adverse effects, and can even exacerbate disease progression.
In this project, we will advance a new class of gut-stable peptide analgesics to target abdominal pain at its origin in the gut. This represents a highly innovative treatment strategy with a large safety window due to its gut-specific action and negligible risk of systemic off-target effects. It also addresses a long-standing problem in the peptide therapeutics industry, namely the lack of oral peptide drugs. The objective of this project is to optimise our patented lead compounds towards oral drug candidates and generate robust and supporting preclinical data for clinical translation.
The proof-of-concept data will then be used to engage with industry partners and other supporters to advance these drug candidates into the clinic for the treatment of chronic abdominal pain. Our gut-specific treatment approach along with this new class of analgesics could induce a highly desired paradigm shift in how to treat chronic abdominal pain and gastrointestinal disorders, an area with unprecedented unmet medical need.
This could benefit millions of people worldwide, improve their quality of life, and help reduce the substantial socio-economic burden that chronic abdominal pain has on society.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Universitat Wien | Wien | Austria | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI